DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A safety and tolerability laboratory study of the combination of aripiprazole and topiramate in volunteers who drink alcohol.

Author(s): Kenna GA, Leggio L, Swift RM

Affiliation(s): Department of Psychiatry and the Center for Alcohol and Addiction Studies, Brown University, Providence, Rhode Island, USA. George_Kenna@Brown.edu

Publication date & source: 2009-08, Hum Psychopharmacol., 24(6):465-72.

Publication type: Randomized Controlled Trial

OBJECTIVE: There are no reports examining the safety of taking both topiramate and aripiprazole together with alcohol. The ultimate aim for this research is to determine whether this combination is safe and is superior to either drug taken alone in reducing alcohol use in alcohol dependent patients. METHOD: This was an open-label trial. Thirteen heavy drinking participants not seeking treatment for alcoholism were randomized. Participants were titrated up to 300 mg of topiramate and 30 mg of aripiprazole a day over 35 days. Participants reported adverse events (AEs) daily alcohol use and participated in an alcohol challenge session (ACS). RESULTS: The eight participants who completed the study achieved the maximum doses of drugs. The AEs of the drugs would suggest that the AEs profile is broader but not additive. Alcohol use from the 28 days before screening to the seven days before the ACS was reduced (p = 0.08). CONCLUSION: There was no evidence that AEs of aripiprazole and topiramate are additive and can, therefore, be administered safely together with a modest amount of alcohol. There was also a trend for a reduction of alcohol use by participants. This finding has implications for further investigation of this combination of drugs for alcohol dependence. 2009 John Wiley & Sons, Ltd.

Page last updated: 2010-10-05

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017